A phase ii study on the effect of taurisolo® administered via aerosol in hospitalized patients with mild to moderate covid-19 pneumonia: the taerovid-19 study

HIGHLIGHTS

• who: Stefano Sanduzzi Zamparelli et al. from the University of Campania "Luigi Vanvitelli", ACardarelli Hospital, Naples, Italy have published the paper: A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study, in the Journal: Cells 2022, 11, 1499. of /2022/
• what: In fact, this trial demonstrated that, even if in a small group of patients, topic administration of this drug via the aerosolic route could be considered safe in COVID-19 patients.
• how: Methods the authors conducted . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.